Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Pfizer’s Chinese drug acquisition ... Expect a mob of Wall Street analysts and investors. AstraZeneca’s plenary streak continues: This is the seventh consecutive year that AstraZeneca has ...

David Fredrickson, executive vice president of AstraZeneca's oncology business ... therapy than if you wait till a second one." Pfizer impresses in colorectal cancer – The company's pill ...

AstraZeneca wins big (again ... from a more effective frontline therapy than if you wait till a second one." Pfizer impresses in colorectal cancer – The company's pill Braftovi, combined ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...